<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>§ 306-8 Schedule III. | Menominee Indian Tribe of Wisconsin Law Library</title>
    <link rel="shortcut icon" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/nsn/menominee/legislature/code/II/306/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/nsn/menominee/legislature/code/II/306/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/nsn/menominee/legislature/code" data-document="href"/>
    <meta itemprop="order" content="|II|306|1|II|306-8|"/>
    <meta itemprop="doc-type" content="section" data-document=""/>
    <meta itemprop="doc-num" content="306-8"/>
    <meta itemprop="ref-doc" content="Code of the Menominee Indian Tribe" data-document=""/>
    <meta itemprop="ref-path" content="II|§306-8" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="/us/nsn/menominee/legislature/code/II/306-8"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="§ 306-8 Schedule III. | Menominee Indian Tribe of Wisconsin Law Library"/>
    <meta property="og:image" content="/us/nsn/menominee/legislature/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#071346"/>
    <meta name="apple-mobile-web-app-title" content="Menominee Indian Tribe of Wisconsin Law Library"/>
    <meta name="theme-color" content="#071346"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/safari-pinned-tab.svg" color="#071346"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/nsn/menominee/legislature/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/nsn/menominee/legislature/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/nsn/menominee/legislature/_document/v2/fonts/ananda/ananda.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/nsn/menominee/legislature/_document/v2/fonts/roboto-condensed/roboto-condensed.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/nsn/menominee/legislature/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/nsn/menominee/legislature/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/nsn/menominee/legislature/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/nsn/menominee/legislature/code/II/306/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/nsn/menominee/legislature/code/II/306/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__menominee-nsn">
      <header id="section__header" class="ns__document__menominee-nsn">
        <div id="section__header__inner" class="ns__document__menominee-nsn">
          <div id="area__logo" class="ns__document__menominee-nsn">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/nsn/menominee/legislature/_document/v2/images/logo/logo.png" srcset="/us/nsn/menominee/legislature/_document/v2/images/logo/logo.png 1x, /us/nsn/menominee/legislature/_document/v2/images/logo/logo@2x.png 2x, /us/nsn/menominee/legislature/_document/v2/images/logo/logo@3x.png 3x" alt="Law Library of the Menominee Indian Tribe logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__menominee-nsn">
            <span class="h__library-title">Menominee Indian Tribe of Wisconsin Law Library</span>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__menominee-nsn">
        <div id="section__content__inner" class="ns__document__menominee-nsn">
          <section id="area__breadcrumbs" class="ns__document__menominee-nsn" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Menominee Indian Tribe of Wisconsin Law Library">Menominee Indian Tribe of Wisconsin Law Library</a>
                </li>
                <li data-search-path="library|Code of the Menominee Indian Tribe" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/nsn/menominee/legislature/code" title="Code of the Menominee Indian Tribe">Code of the Menominee Indian Tribe</a>
                </li>
                <li data-search-path="library|Code of the Menominee Indian Tribe|II" data-search-heading="">
                  <a href="/us/nsn/menominee/legislature/code/II" title="Part II General Legislation">Part II General Legislation</a>
                </li>
                <li data-search-path="library|Code of the Menominee Indian Tribe|II|306" data-search-heading="">
                  <a href="/us/nsn/menominee/legislature/code/II/306" title="Chapter 306 DRUGS AND DRUG PARAPHERNALIA">Chapter 306 DRUGS AND DRUG PARAPHERNALIA</a>
                </li>
                <li data-search-path="library|Code of the Menominee Indian Tribe|II|306|1" data-search-heading="">
                  <a href="/us/nsn/menominee/legislature/code/II/306/1" title="Part 1 Controlled Substances">Part 1 Controlled Substances</a>
                </li>
                <li data-search-path="library|Code of the Menominee Indian Tribe|II|306|1|II" data-search-heading="">
                  <a href="/us/nsn/menominee/legislature/code/II/306/1/II" title="Article II Provisions for Scheduling; Schedules I, II, III, IV and V">Article II Provisions for Scheduling; Schedules I, II, III, IV and V</a>
                </li>
                <li data-search-path="library|Code of the Menominee Indian Tribe|II|306|1|II|306-8" data-search-heading="">
                  <span title="§ 306-8 Schedule III.">§ 306-8 Schedule III.</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__menominee-nsn">
            <div class="h__document-title">Code of the Menominee Indian Tribe</div>
            <article class="content" role="document" data-ref-path="II|§306-8">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/nsn/menominee/legislature/code/II/306-8">§ 306-8 Schedule III.</h1>
                <p>Unless specifically excepted by tribal regulation or unless listed in another schedule, any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, are listed in Schedule III:</p>
                <p class="text-indent-1 "><span class="level-num" id="A.">A.</span> Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>
                <p class="text-indent-2 "><span class="level-num" id="A.(1)">(1)</span> Benzphetamine.</p>
                <p class="text-indent-2 "><span class="level-num" id="A.(2)">(2)</span> Chlorphentermine.</p>
                <p class="text-indent-2 "><span class="level-num" id="A.(3)">(3)</span> Clortermine.</p>
                <p class="text-indent-2 "><span class="level-num" id="A.(4)">(4)</span> Phendimetrazine.</p>
                <p class="text-indent-1 "><span class="level-num" id="B.">B.</span> Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(1)">(1)</span> Any compound, mixture or preparation containing:</p>
                <p class="text-indent-3 "><span class="level-num" id="B.(1)(a)">(a)</span> Amobarbital;</p>
                <p class="text-indent-3 "><span class="level-num" id="B.(1)(b)">(b)</span> Secobarbital;</p>
                <p class="text-indent-3 "><span class="level-num" id="B.(1)(c)">(c)</span> Pentobarbital; or</p>
                <p class="text-indent-3 "><span class="level-num" id="B.(1)(d)">(d)</span> Any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(2)">(2)</span> Any suppository dosage form containing:</p>
                <p class="text-indent-3 "><span class="level-num" id="B.(2)(a)">(a)</span> Amobarbital;</p>
                <p class="text-indent-3 "><span class="level-num" id="B.(2)(b)">(b)</span> Secobarbital;</p>
                <p class="text-indent-3 "><span class="level-num" id="B.(2)(c)">(c)</span> Pentobarbital; or</p>
                <p class="text-indent-3 "><span class="level-num" id="B.(2)(d)">(d)</span> Any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(3)">(3)</span> Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(4)">(4)</span> Chlorhexadol.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(5)">(5)</span> Embutramide.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(6)">(6)</span> Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under Section 505 of the Federal Food, Drug, and Cosmetic Act.<a class="footnote-anchor" id="note-2" href="#footnote-2" aria-labelledby="footnote-2">2</a></p>
                <p class="text-indent-2 "><span class="level-num" id="B.(7)">(7)</span> Ketamine, its salts, isomers, and salts of isomers [some other names for ketamine: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone].</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(8)">(8)</span> Lysergic acid.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(9)">(9)</span> Lysergic acid amide.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(10)">(10)</span> Methyprylon.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(11)">(11)</span> Sulfondiethylmethane.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(12)">(12)</span> Sulfonethylmethane.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(13)">(13)</span> Sulfonmethane.</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(14)">(14)</span> Tiletamine and zolazepam or any salt thereof (some trade or other names for a tiletamine-zolazepam combination product: Telazol; some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone; some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one, flupyrazapon).</p>
                <p class="text-indent-2 "><span class="level-num" id="B.(15)">(15)</span> Nalorphine 9400.</p>
                <p class="text-indent-1 "><span class="level-num" id="C.">C.</span> Narcotic drugs. Unless specifically excepted or unless listed in another schedule:</p>
                <p class="text-indent-2 "><span class="level-num" id="C.(1)">(1)</span> Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:</p>
                <p class="text-indent-2 "><span class="level-num" id="C.(2)">(2)</span> Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.</p>
                <p class="text-indent-2 "><span class="level-num" id="C.(3)">(3)</span> Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</p>
                <p class="text-indent-2 "><span class="level-num" id="C.(4)">(4)</span> Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.</p>
                <p class="text-indent-2 "><span class="level-num" id="C.(5)">(5)</span> Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.</p>
                <p class="text-indent-2 "><span class="level-num" id="C.(6)">(6)</span> Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.</p>
                <p class="text-indent-2 "><span class="level-num" id="C.(7)">(7)</span> Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</p>
                <p class="text-indent-2 "><span class="level-num" id="C.(8)">(8)</span> Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</p>
                <p class="text-indent-2 "><span class="level-num" id="C.(9)">(9)</span> Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</p>
                <p class="text-indent-1 "><span class="level-num" id="D.">D.</span> Narcotic drugs not limited by quantity. Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:</p>
                <p class="text-indent-2 "><span class="level-num" id="D.(1)">(1)</span> Buprenorphine.</p>
                <p class="text-indent-2 "><span class="level-num" id="D.(2)">(2)</span> (Reserved)</p>
                <p class="text-indent-1 "><span class="level-num" id="E.">E.</span> Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers:</p>
                <p class="text-indent-2 "><span class="level-num" id="E.(1)">(1)</span> Anabolic steroids. (See § 306-3 of <a class="internal-link no-wrap" href="/us/nsn/menominee/legislature/code/II/306/1" title="Part 1 Controlled Substances">this Part</a> 1.)</p>
                <p class="text-indent-2 "><span class="level-num" id="E.(2)">(2)</span> (Reserved)</p>
                <p class="text-indent-1 "><span class="level-num" id="F.">F.</span> Hallucinogenic substances.</p>
                <p class="text-indent-2 "><span class="level-num" id="F.(1)">(1)</span> Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved product [some other names for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-ol] or (-)-delta-9-(trans)-tetrahydrocannabinol].</p>
                <p class="text-indent-2 "><span class="level-num" id="F.(2)">(2)</span> (Reserved)</p>
                <section role="doc-endnotes" aria-labelledby="footnote-heading">
                  <ol class="footnotes" start="1">
                    <li role="doc-endnote" id="footnote-2">
                      <a href="#note-2">2.
      </a>
                      <p>Editor's Note: See 21 U.S.C. § 301 et seq.</p>
                    </li>
                  </ol>
                </section>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__menominee-nsn" aria-label="Previous and next article links">
            <section>
              <a href="/us/nsn/menominee/legislature/code/II/306-7" aria-label="§ 306-7 Schedule II.">
                <div class="h__ui">Previous</div>
                <span>§ 306-7 Schedule II.</span>
              </a>
            </section>
            <section>
              <a href="/us/nsn/menominee/legislature/code/II/306-9" aria-label="§ 306-9 Schedule IV.">
                <div class="h__ui">Next</div>
                <span>§ 306-9 Schedule IV.</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__menominee-nsn">
        <div id="section__footer__inner" class="ns__document__menominee-nsn">
          <div id="area__footer__content" class="ns__document__menominee-nsn">
            <p>The codes and laws on this website are in the public domain.</p>
            <p>
      Please do not scrape. Instead, bulk download the <a href="https://github.com/menominee-nsn/law-html">HTML</a> or <a href="https://github.com/menominee-nsn/law-xml">XML</a>.
    </p>
            <p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p>
          </div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
